Novo Nordisk (NVO-NYSE, $187.57) and Eli Lilly (LLY-NYSE, $517.53) Seek to Potentially Upend Modern Preventative Healthcare. There Will be Winners and Losers.
A key study, detailed today, published by Novo Nordisk, confirm what has been widely assumed by medical researchers in the rather new GLP-1 medication class; that in addition to providing quantifiable and fairly immediate benefits for those with type 2…
Posted in Open Blog